Research Strategy:

• This research project is focused on summarizing evidence from scientific studies regarding the therapeutic role of CBD in the treatment of metabolic dysfunctional disease, and the diseases associated with hormone imbalances. We used Clinicaltrials.gov and PubMed to search for clinical trials and clinical studies related to CBD, which was our main priority for this research project. Since clinical trials were limited, we also included preclinical studies. We covered the therapeutic roles of CBD as anti-seizure, neuroprotective, anti-inflammatory, analgesic, and anti-tumor effects. Kindly find the systematic review of literature in the attached google spreadsheet. 
• Our research indicated that much of the clinical trials and human clinical studies have focused on a range of Cannabinoids including Tetrahydrocannabinol (THC), Medical Marijuana, other forms of plant-based Cannabinoids, and Cannabidiol+THC. Very few human clinical studies and trials have solely investigated the therapeutic role of (pure) CBD for the treatment of systemic diseases, which have been either been covered in the first part of this research and some in the second part (current research). Most of the studies on CBD are largely based on pre-clinical models that include cell lines, mouse models, and higher mammalian models which have also been presented in this research literature synthesis.  
• A recent review article (Ashwani S Patil. et. al., 2020) has compiled a list of preclinical and clinical studies that investigated the therapeutic role of Cannabinoids in treating Metabolic dysfunctional diseases including metabolic syndrome, stoutness, fatty acid liver diseases, insulin obstruction, dementia, hypertension, lipid abnormalities, non-alcoholic steatohepatitis, endothelial damage, and polycystic ovarian syndrome. Some findings of this article have also been summarized in the attached google spreadsheet.

Preliminary Research:

• The figure below summarized the different therapeutic effects of cannabinoids (CBD) on the human body.

•  
  Source
   
• Currently, most of the evidence around the pharmacological role of CBD is generated from preclinical models based on receptor-drug interactions. The following schematic summarized areas where CB1 and CB2 receptors are positioned in the human body and could be potential therapeutic targets for CBD in the management of the Metabolic Syndrome. However, to-date the clinical evidence using CBD for the management of diseases associated with Metabolic dysfunction is lacking.
•  
  Source